{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-25-009137","form_type":"8-K","ticker":"QNRX","cik":"0001671502","company_name":"Quoin Pharmaceuticals, Ltd.","filed_at":"2025-02-04T23:59:59+00:00","discovered_at":"2026-05-14T18:03:04.385341+00:00","generated_at":"2026-05-27T03:32:07.407615+00:00","sec_items":["8.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.2,"calibrated_materiality_score":0.2,"confidence":"high","headline":"Quoin launches Netherton NOW campaign for rare disease awareness","bullets":["Campaign 'NETHERTON NOW' launched Feb 4, 2025 to raise awareness for Netherton Syndrome.","20% of babies with Netherton Syndrome estimated not to survive, per company.","Quoin has four ongoing clinical studies evaluating QRX003 for Netherton Syndrome.","As of Feb 4, 2025, outstanding ordinary shares (ADS) total 20,585,830."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-25-009137","json":"https://secwatch.observer/filing/0001104659-25-009137.json","markdown":"https://secwatch.observer/filing/0001104659-25-009137.md","text":"https://secwatch.observer/filing/0001104659-25-009137.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1671502/000110465925009137/0001104659-25-009137-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1671502/000110465925009137/tm255460d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-27T03:32:07.407615+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}